Therefore, clinical and in-vitro experiment results indicate that in the patients with cardiac arrest, kallistatin can be a potential prognostic indicator and therapeutic agent for the patient's neurological prognosis. This evidence concerns the gene SERPINA4 and cardiac arrest.